Back to results
CompletedPhase 2

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00104273

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Collaborative Neuroscience Network

Huntsville, Alabama, United States

+57 additional locations

View on ClinicalTrials.gov